ArticleWorld journal of surgical oncology2025
Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe role of EGFR-TKIs as adjuvant therapy for stage IA lung adenocarcinoma after surgery remains controversial. Though 5-year OS of stage IA patients reaches 88%, the 5-year DFSs of IA1, IA2, and IA3 vary a lot, 88.2%, 73.6% and 64.5%, respectively. This study specifically evaluated the clinical efficacy of postoperative EGFR-TKI therapy in stage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors.
methodsStage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors at Jinling Hospital from January 1, 2017 to December 31, 2021 were collected. Eligible patients were grouped into EGFR-TKI therapy group and non-EGFR-TKI therapy group. Subgroup analysis was performed to explore potential benefits of adjuvant EGFR-TKI therapy.
resultsThe study cohort comprised 221 eligible patients, among which 42 patients received postoperative adjuvant EGFR-TKI therapy. The median duration of follow-up was 49 months(IQR: 38-63). There was no statistically significant difference in DFS between the adjuvant EGFR-TKI therapy group and the non-EGFR-TKI therapy group (P = 0.080). In subgroup analysis for cohorts receiving lobectomy, adjuvant EGFR-TKI therapy group had a better DFS than non-adjuvant EGFR-TKI therapy group (P = 0.024). Tumor size (HR = 1.071, 95%CI:1.010-1.136, P = 0.024) and adjuvant EGFR-TKI therapy (HR = 0.124, 95%CI:0.017-0.912, P = 0.040) were both independent significant prognostic factors for DFS in the lobectomy subgroup.
conclusionsGenerally, postoperative EGFR-TKI therapy might provide no significant clinical benefits for stage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors. However, in specific subgroup, such as patients receiving lobectomy, EGFR-TKI therapy shows potential benefit which requires further exploration in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.